Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PAM | P19021 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6898155 | 1.00 | PRMT1 (0.50) | PRMT1RAB9AMAOBKDM4EPAM | |
| SCHEMBL11597357 | 0.88 | PRMT1 (0.55) | PRMT1RAB9AMAOBKDM4EPAM | |
| SCHEMBL11597360 | 0.88 | PRMT1 (0.55) | PRMT1RAB9AMAOBKDM4EPAM | |
| Hydrochloric Acid SCHEMBL29221170 | 0.87 | PRMT1 (0.47) | PRMT1RAB9AMAOBKDM4EPAM | |
| Hydrochloric Acid SCHEMBL29221168 | 0.87 | PRMT1 (0.47) | PRMT1RAB9AMAOBKDM4EPAM | |
| SCHEMBL2770961 | 0.83 | KDM4E (0.55) | PRMT1RAB9AMAOBKDM4EPAM | |
| SCHEMBL2770965 | 0.83 | KDM4E (0.55) | PRMT1RAB9AMAOBKDM4EPAM | |
| SCHEMBL4948645 | 0.81 | PRMT1 (0.54) | PRMT1RAB9AMAOBKDM4EALDH1A1 | |
| SCHEMBL28725423 | 0.81 | PRMT1 (0.54) | PRMT1RAB9AMAOBKDM4EALDH1A1 | |
| SCHEMBL3299029 | 0.81 | RAB9A (0.50) | PRMT1RAB9AMAOBKDM4EPAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1305846-C | Urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2007-03-21 | — | — | CN | disclosed |
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | PRMT1 468/4885RAB9A 3117/4885MAOB 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.